Imexpharm Corp (IMP)

Currency in VND
51,800.0
-100.0(-0.19%)
Closed·
IMP Scorecard
Full Analysis
Trading at a high P/E ratio relative to near-term earnings growth
IMP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
51,700.052,000.0
52 wk Range
36,100.056,500.0
Key Statistics
Bid/Ask
51,800.00 / 51,900.00
Prev. Close
51,900
Open
51,900
Day's Range
51,700-52,000
52 wk Range
36,100-56,500
Volume
130.9K
Average Vol. (3m)
175.08K
1-Year Change
18.9%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
44,833.3
Downside
-13.45%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Imexpharm Corp Company Profile

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and supplies, chemicals, materials for medicine manufacturing and packaging, and chemicals used for sterilization or disinfection in humans. The company was founded in 1977 and is headquartered in Cao Lanh, Vietnam.

Employees
1446
Market
Vietnam

Compare IMP to Peers and Sector

Metrics to compare
IMP
Peers
Sector
Relationship
P/E Ratio
25.9x18.7x−0.5x
PEG Ratio
1.500.170.00
Price / Book
3.6x2.0x2.6x
Price / LTM Sales
3.5x1.2x3.2x
Upside (Analyst Target)
−15.8%17.5%45.3%
Fair Value Upside
Unlock8.9%7.4%Unlock

Analyst Ratings

1 Buy
1 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 44,833.3
(-13.45% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2,007.45%
Dividend Yield
0.97%
Annualized Payout
500.00
Paid annually
5-Years Growth
+8.47%
Growth Streak

Earnings

Latest Release
May 28, 2025
EPS / Forecast
448.34 / --
Revenue / Forecast
594.00B / 491.00B
EPS Revisions
Last 90 days

IMP Income Statement

People Also Watch

56,500.0
TDM
-2.59%
37,700.0
BIC
-1.44%
36,800.0
BHN
+0.27%
64,300.0
AST
+0.16%
297,200
VCF
+0.30%

FAQ

What Is the Imexpharm Corp (IMP) Stock Price Today?

The Imexpharm Corp stock price today is 51,800.00

What Stock Exchange Does Imexpharm Corp Trade On?

Imexpharm Corp is listed and trades on the Ho Chi Minh City Stock Exchange stock exchange.

What Is the Stock Symbol for Imexpharm Corp?

The stock symbol for Imexpharm Corp is "IMP."

Does Imexpharm Corp Pay Dividends? What’s The Current Dividend Yield?

The Imexpharm Corp dividend yield is 0.97%.

What Is the Imexpharm Corp Market Cap?

As of today, Imexpharm Corp market cap is 7.98T.

What Is Imexpharm Corp's Earnings Per Share (TTM)?

The Imexpharm Corp EPS (TTM) is 2,007.45.

When Is the Next Imexpharm Corp Earnings Date?

Imexpharm Corp will release its next earnings report on Sep 03, 2025.

From a Technical Analysis Perspective, Is IMP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Imexpharm Corp Stock Split?

Imexpharm Corp has split 11 times.

How Many Employees Does Imexpharm Corp Have?

Imexpharm Corp has 1446 employees.

What is the current trading status of Imexpharm Corp (IMP)?

As of Jul 16, 2025, Imexpharm Corp (IMP) is trading at a price of 51,800.00, with a previous close of 51,900.00. The stock has fluctuated within a day range of 51,700.00 to 52,000.00, while its 52-week range spans from 36,100.00 to 56,500.00.

What Is Imexpharm Corp (IMP) Price Target According to Analysts?

The average 12-month price target for Imexpharm Corp is VND44833.33333, with a high estimate of VND49000 and a low estimate of VND41800. 1 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an -13.45% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.